Botulinum toxin B reduces sialorrhea in parkinsonism

Authors

Brad A. Racette, Department of Neurology and Neurological Surgery, Washington University School of Medicine, St. Louis, Missouri 63110, USA. racetteb@neuro.wustl.edu
Laura Good
Sandy Sagitto
Joel S. Perlmutter

Document Type

Article

Abstract

We report on our open-label experience with botulinum toxin B for the treatment of severe sialorrhea associated with parkinsonism. Nine adult patients with parkinsonism and medically intractable sialorrhea were treated with botulinum toxin B (1,000 units into each parotid gland using superficial landmarks). After treatment, patients experienced a 61% mean subjective improvement and a 42% mean reduction of quantitative saliva production. There were no adverse effects seen in any subjects. Mean peak benefit from injections lasted 14 weeks. We conclude that denervation of salivary glands with botulinum toxin B produces excellent reduction of excessive salivation associated with parkinsonism.

Medical Subject Headings

Aged; Aged, 80 and over; Botulinum Toxins (therapeutic use); Botulinum Toxins, Type A; Humans; Middle Aged; Parkinsonian Disorders (complications); Salivation (drug effects); Sialorrhea (drug therapy, etiology); Treatment Outcome

Publication Date

9-1-2003

Publication Title

Movement disorders : official journal of the Movement Disorder Society

ISSN

0885-3185

Volume

18

Issue

9

First Page

1059

Last Page

61

PubMed ID

14502678

Digital Object Identifier (DOI)

10.1002/mds.10484

Recommended Citation

Racette, Brad A.; Good, Laura; Sagitto, Sandy; and Perlmutter, Joel S., "Botulinum toxin B reduces sialorrhea in parkinsonism" (2003). Neurology. 1107.
https://scholar.barrowneuro.org/neurology/1107